03.11.2012 • NewsDendreonQ3 2012sales and profits

Dendreon Posts Better-Than-Expected Q3 Results

Dendreon on Friday said restructuring-related costs widened its quarterly loss but not as much as Wall Street had expected, and its shares jumped 20%.

The biotech company said sales of its prostate cancer treatment Provenge rose and noted that the reimbursement landscape for therapy had improved. It said accounts at community hospitals improved, though utilization at academic centers fell.

"Provenge sales were up year-over-year, so that was a positive, and there's evidence that their cost-cutting initiatives are starting to take hold," said Morningstar analyst Lauren Migliore. "There seems to be some good momentum for future Provenge growth."

The company posted a third-quarter net loss of $154.9 million, or $1.04 per share, compared with a loss of $147.1 million, or $1.00 per share, a year ago.

Excluding certain items, the company lost 59 cents. On that basis, analysts on average had expected an 86-cent loss, according to Thomson Reuters I/B/E/S.

Quarterly revenue rose to $78.0 million from $64.3 million.

Dendreon said its restructuring is on track and that it expects to see benefits associated with the initiative to be fully realized in the third quarter of 2013.

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.